] . Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76. 
(803.67 KB)
(803.67 KB). The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159. (476.19 KB)
(476.19 KB). Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41. (144.71 KB)
(144.71 KB). The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55. (470.91 KB)
(470.91 KB). Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51. (153.93 KB)
(153.93 KB). Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113. (412.73 KB)
(412.73 KB). The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81. (233.18 KB)
(233.18 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB). Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27. (201.46 KB)
(201.46 KB)